Comparative Pharmacology
Head-to-head clinical analysis: NIMBEX versus ZEMURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMBEX versus ZEMURON.
NIMBEX vs ZEMURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and inducing muscle relaxation.
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing muscle contraction.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 1-2 mcg/kg/min (initial) adjusted to effect.
0.6-1.2 mg/kg IV bolus for intubation; maintenance 0.1-0.2 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life approximately 20-30 minutes in healthy adults; prolonged in hepatic or renal impairment.
Terminal elimination half-life is approximately 2.3 hours (range 1.7-3.1 hours) in adults with normal renal function. Clinical context: May be prolonged in hepatic or renal impairment.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal excretion accounts for <20%.
Primarily renal (70-80% as unchanged drug and metabolites) and biliary (20-30% as unchanged drug and metabolites).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent